Epizyme, a clinical stage biopharmaceutical company focused on therapeutics for patients with...

|By:, SA News Editor

Epizyme, a clinical stage biopharmaceutical company focused on therapeutics for patients with genetically defined cancers, files for a 4.285M share IPO. The company hasn't set an expected price range as of yet, but plans to list on the The Nasdaq Global Market under the symbol "EPZM." The offering will be made through Citigroup, Cowen, Leerink Swann, JMP Securities, and Wedbush PacGrow Life Sciences.